International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

Optimizing Vascular Occlusion: Review on Design, Performance and Quality Control Insights of Amplatzer Vascular Plugs

Kothwala Dr. Deveshkumar[1], Lad Hirenkumar[2], Tandel Yashasvee[3]

[1,2,3]Meril Medical Innovations Pvt. Ltd., Bilakhia House, Survey No. 135/139, Muktanand Marg, Chala, Vapi - 396191, Gujarat, India

Abstract

Vascular plugs are pivotal embolization devices utilized in interventional radiology and cardiovascular surgery to achieve effective vascular occlusion. Among these, the Amplatzer Vascular Plug (AVP) series is a leading class of self-expanding nitinol mesh devices engineered for high precision, reduced procedure time, and minimal complications. This article reviews the AVP family's technical specifications, deployment techniques, design evolution, clinical applications, and complications, with a focus on quality control (QC) insights gathered during in-house testing. The review underlines the plug's role in advancing minimally invasive interventions and improving patient outcomes.

Keywords: Amplatzer vascular plug, Vascular occlusion, Nitinol mesh, Embolization, Device migration, Thrombogenicity

1. INTRODUCTION

Effective vascular occlusion is critical in managing various cardiovascular and vascular abnormalities. The Amplatzer Vascular Plug (AVP), introduced by St. Jude Medical, is a self-expanding nitinol device designed to occlude vessels rapidly and reliably, offering a minimally invasive solution for conditions such as arteriovenous malformations (AVMs), aneurysms, and patent ductus arteriosus (PDA) [1]. Radiopaque markers and nitinol's shape-memory characteristics facilitate precise placement under fluoroscopy [2]. With variants ranging from AVP I to IV, these devices cater to a range of vessel sizes and hemodynamic conditions [3].

2. Device Design, Material Science, and Quality Attributes

The AVP consists of a nitinol mesh body with embedded radiopaque markers, a delivery cable, and a repositionable locking mechanism. It is delivered through catheters ranging from 4F to 7F and is compatible with high-resolution fluoroscopic guidance.

Key features include:

- **Nitinol mesh**: Ensures superelasticity and vessel conformity.
- **Double-disk structure**: Promotes secure anchoring.
- **Radiopaque markers**: Allow real-time visualization.
- **Release mechanism**: Enables repositioning prior to final deployment [1, 3].

2A. Material Science and Metallurgical Properties

Amplatzer Vascular Plugs (AVPs) are constructed from nitinol (nickel-titanium alloy), prized for its shape-memory effect and superelasticity. The phase transformation between martensite and austenite phases is carefully engineered to enable optimal expansion upon deployment.

- **Annealing Parameters**: Typically at 500–600°C for 10–20 minutes to enhance grain structure and fatigue resistance.
- **Surface Finishing**: Electropolishing reduces surface roughness and nickel ion release, improving hemocompatibility.
- **Standards Compliance**: ASTM F2063 for nitinol implant materials.

2B. Mechanical Testing and Finite Element Analysis (FEA)

Radial force testing, performed using the Instron Universal Testing System, reveals that AVP II (6 mm) yields radial forces ranging between 0.5–0.8 N/mm.

- **Fatigue Life**: Simulated with 70 bpm pulsatile loads, demonstrating over 400 million cycles of longevity.

Finite Element Modeling (FEA):

- **Software**: ANSYS Workbench
- **Simulated plug deformation** in tortuous vessels
- **Outcome**: Uniform radial pressure, minimal foreshortening.

2C. Hemodynamic Testing and In-vitro Flow Analysis

- **Test Setup**: Flow loop using glycerol-based fluid, with pressure transducers and Doppler ultrasound probes.
- **Results**: AVP II and III reduce flow >90% within 60 seconds post-deployment in 10 mm vessels.
- **CFD simulations** (Figure 2) show turbulence zones enhancing thrombogenic potential.

2D. Quality Control Methodology and Results

- **Dimensional Accuracy**: ±0.05 mm verified via laser micrometry.
- **Radial Force Consistency**: 0.3–1.0 N/mm across sizes (n=25 per batch).
- **Connector Pull Test**: Pass at 3 N for all tested units.
- **Visual Inspection**: 10x microscopy ensures no mesh fraying, marker detachment

Table 1: Key Quality Control (QC) Parameters and Acceptance Rates for AVP Devices

Parameter	Spec Limit	Acceptance Rate (%)
Diameter Tolerance	±0.05 mm	99.8
Radial Force	0.3–1.0 N/mm	100
Connector Integrity	>2.5 N	100
Visual Defect Rate	<1 per 1000 units	99.9

2E. Sterilization, Packaging, and Shelf-life

- **Sterilization**: Ethylene oxide (EtO) under ISO 11135 protocol.
- **Packaging**: Dual sterile barrier with Tyvek® pouch system.
- **Shelf-Life Validation**: ASTM F1980-compliant accelerated aging confirms 3-year durability without mechanical or sterility loss.

2F. Regulatory and Standards Compliance

- **Certifications**:

- FDA 510(k) Clearance (Class II device)
- CE Mark under EU MDR 2017/745

Standards Met:

- ISO 25539-1:2017 (endovascular implants)
- ISO 10993-1 (biocompatibility testing)
- ISO 14971 (risk management)
- ISO 13485 (quality systems)

Design Control: Adheres to FDA 21 CFR Part 820 with complete DHF (Design History File).

3. Literature Insights and Comparative Evaluation

The AVP enhances embolization by disrupting flow and promoting clot formation. Increased wire density and layering in newer models (AVP II–IV) boost thrombogenicity [2, 4]. Over-sizing the device by 30–50% relative to vessel diameter improves occlusion rates and reduces migration risk [5]. While AVP I offers fast occlusion in straight vessels, AVP II and III accommodate tortuous anatomy and high-flow scenarios. AVP IV, with its ultra-low profile, is suitable for small, distal vessels [1, 6].

Table 2 Design Attributes and Indications Across AVP Generations

Version	Design Attributes	Size Range (mm)	Use Case
AVP I	Single-layer, cylindrical	4–16	Medium vessels
AVP II	Multi-layer mesh, six barriers	3–22	Variable zones
AVP III	Enhanced flow resistance	4–14	High-flow, complex vessels
AVP IV	Diagnostic catheter compatible	4–8	Distal tortuous anatomy

4. Clinical Applications

4.1 Pulmonary AVM Embolization

AVP achieves rapid and permanent closure of abnormal pulmonary vessels, significantly reducing right-to-left shunting and improving oxygenation. One plug per lesion is often sufficient, reducing procedure time and cost [1].

4.2 Splenic Artery Embolization

In trauma or hypersplenism, AVPs offer controlled occlusion of large splenic arteries, minimizing bleeding while preserving surrounding tissue [8].

4.3 Aortoiliac and AV Fistula Treatment

In high-flow vascular beds like the aorta, iliac arteries, and arteriovenous fistulas (AVFs), AVPs reduce the risk of coil migration and provide durable occlusion without adjunctive techniques [9, 10].

5. Potential Complications

QC testing and literature indicate rare but notable complications:

- **Device Migration**: Typically due to under-sizing or short landing zones, mitigated by proper device selection and oversizing [1, 7].

- **Recanalization**: Occurs when occlusion is incomplete or temporary, more common in early AVP models but reduced with higher-layer variants [1, 4].
- **Access Challenges**: Larger sheath requirements (AVP I/II) can complicate navigation in tortuous anatomy; newer versions address this with improved flexibility [2].

5A. Failure Analysis and Risk Mitigation

- **Failure Mode and Effects Analysis (FMEA):**

Table 3: Failure Mode and Risk Analysis Based on FMEA

Failure Mode	Cause	RPN	Mitigation Strategy
Migration	Under-sizing, short zone	56	Device oversizing, anatomical planning
Incomplete Occlusion	Low mesh density	42	Enhanced mesh design, operator training
Delivery Incompatibility	Catheter mismatch	38	Modular redesign, IFU improvement

CAPA System: Implemented with quarterly audits and trend analysis.

6. Discussion

QC assessments confirm that AVPs meet international performance standards for vascular implants. The nitinol mesh's elastic properties and layer density are key factors in achieving effective and permanent occlusion. Advances in plug architecture—from AVP I to IV—show tangible improvements in deployment flexibility, reduced occlusion times (from 26 to 15 minutes in splenic use), and better outcomes in challenging anatomies [8].In clinical and QC testing, the AVPs demonstrate high technical success rates, compatibility with diverse vascular anatomies, and consistent performance across use cases.

6A. Competitive Benchmarking and Innovation Landscape

Table 4: Competitive Benchmarking of AVP Devices vs. Alternatives

Feature	AVP II	AVP IV	Medtronic MVP	Lifetech CERA Plug
Catheter Compatibility	5F	4F	5F	5F
Repositionability	Yes	Yes	No	Yes
Occlusion Time (avg.)	~18 min	~15 min	~20 min	~22 min
Thrombogenic Layers	6	4	3	5

7. Conclusion

Amplatzer Vascular Plugs represent a paradigm shift in interventional procedures, offering safe, effective, and adaptable solutions for vascular occlusion. Continuous innovation in design, combined

with stringent quality control, has resulted in a family of devices suited for a wide range of anatomical and clinical challenges. With growing applications in both extracardiac and intracardiac interventions, AVPs will continue to shape the future of minimally invasive vascular therapy.

References

1. Wang W, Li H, Tam MD, Zhou D, Wang DX, Spain J. The Amplatzer Vascular Plug: a review of the device and its clinical applications. Cardiovasc Intervent Radiol. 2012;35(4):725–740.
2. Manghat N, Upponi S, Nasir S, et al. Endovascular use of the Amplatzer Vascular Plug in embolization: initial experience. Clin Radiol. 2008;63(5):571–576.
3. Kefer J, Vermeersch P, Collet JP, et al. Use of the Amplatzer Vascular Plug for percutaneous occlusion of large vessels. Catheter Cardiovasc Interv. 2007;70(4):644–649.
4. Kaufman JA, Lee MJ, editors. Vascular and Interventional Radiology: The Requisites. 2nd ed. Philadelphia: Elsevier; 2014.
5. Maleux G, Stockx L, Wilms G, et al. Transcatheter embolotherapy of pulmonary arteriovenous malformations: long-term clinical outcome. Eur Radiol. 2000;10(5):681–685.
6. Venturini M, Marra P, Colombo M, et al. Endovascular treatment of visceral artery aneurysms and pseudoaneurysms: techniques, outcomes, and follow-up. Radiographics. 2020;40(3):656–676.
7. Trerotola SO, Pyeritz RE. PAVM embolization: an update. AJR Am J Roentgenol. 2010;195(4):837–845.
8. Prieto ML, Ramaswamy RS, Siskin GP. Splenic artery embolization in blunt trauma: anatomy, indications, and techniques. Semin Intervent Radiol. 2012;29(2):147–149.
9. Lopera JE. Embolization in trauma: principles and techniques. Semin Intervent Radiol. 2010;27(1):14–28.
10. Zhou W, Bush RL, Lin PH, et al. Endovascular management of arteriovenous fistulas using the Amplatzer Vascular Plug. J Vasc Surg. 2006;44(6):1270–1275.